NCT00102596 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bikson M, Ghai RS, Baraban SC, Durand DM
Modulation of burst frequency, duration, and amplitude in the zero-Ca(2+) model of epileptiform activity. J Neurophysiol. 1999 Nov;82(5):2262-70.
Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC
Is essential tremor benign? Neurology. 1991 Dec;41(12):1982-3.
Bushara KO, Goldstein SR, Grimes GJ Jr, Burstein AH, Hallett M
Pilot trial of 1-octanol in essential tremor. Neurology. 2004 Jan 13;62(1):122-4.
Fahn S, Tolosa E, Marín C
Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson's Disease and Movement Disorders. 2nd ed. Baltimore: Williams & Wilkins; 1993. p. 225-34.
Nahab FB, Wittevrongel L, Ippolito D, Toro C, Grimes GJ, Starling J, Potti G, Haubenberger D, Bowen D, Buchwald P, Dong C, Kalowitz D, Hallett M
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations o

Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor

Clinical trial NCT00102596 - References